Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic.

Cytisine is a plant-based alkaloid with a high binding affinity to the α4β2 nicotine receptor. Over the past 20 years, it is estimated that over 20 million people have used cytisine to help combat nicotine addiction.  Achieve’s focus is to address the global smoking health epidemic by making cytisine widely available.

Recent News

More News

Smoking is a global public health epidemic responsible for the loss of nearly 6 million lives annually.


Cytisine is a plant-based smoking cessation treatment currently approved in Central and Eastern Europe.

Learn More

Clinical Trials

Phase 3 clinical trials conducted in Europe and New Zealand and published in the New England Journal of Medicine.

Learn More


Achieve is a specialty pharmaceutical company focused global development of cytisine for smoking cessation.

Learn More

Smoking is the #1 cause of preventable deaths worldwide.

According to the Centers for Disease Control and Prevention (CDC), nearly 70% of current smokers have expressed a desire to quit, 40% attempted to quit in the past year, but only 6.2% succeeded.